New Blood-Filtering therapy tested for nerve disease

NCT ID NCT07154524

Recruiting now Disease control Sponsor: University of Ulm Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is testing a blood-filtering treatment called immunoadsorption for people with CIDP, a nerve disorder causing weakness and numbness. About 140 adults who did not get better with standard treatments will be observed for 18 months. The goal is to see if immunoadsorption is safe and helps improve symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: immunoadsorption
What this could lead to: If successful, immunoadsorption could offer a new treatment option for CIDP patients who do not respond to standard therapies like IVIg or steroids.
What could go wrong: This is an early observational study, not a randomized trial, so results may not prove effectiveness. The treatment is only for those who fail other therapies, and its safety and benefit are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

Contacts and locations

Locations

University of Ulm
RECRUITING

Ulm, Baden-Wurttemberg, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.